EOLS.OQ
Latest Trade
5.83USDChange
0.18(+3.19%)Volume
96,744Today's Range
-
5.8852 Week Range
-
11.72As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 5.65 |
|---|---|
Open | 5.66 |
Volume | 96,744 |
3M AVG Volume | 14.29 |
Today's High | 5.88 |
Today's Low | 5.46 |
52 Week High | 11.72 |
52 Week Low | 2.85 |
Shares Out (MIL) | 33.75 |
Market Cap (MIL) | 196.76 |
Forward P/E | -3.00 |
Dividend (Yield %) | -- |
Evolus Inc - On January 4, Co, Oxford Finance Entered Into A Payoff Letter Agreement - SEC Filing
Evolus Inc - On December 16, 2020, ITC Issued Its Final Determination In ITC Action
Evolus Reports Third Quarter 2020 Results And Provides Business Update
Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.
Industry
Biotechnology & Drugs
Contact Info
520 Newport Center Dr Ste 1200
NEWPORT BEACH, CA
92660-7022
United States
+1.949.2844555
https://www.evolus.comExecutive Leadership
Vikram Malik
Chairman of the Board
David Moatazedi
President, Chief Executive Officer, Director
Lauren P. Silvernail
Chief Financial Officer, Executive Vice President - Corporate Development
Jeff Plumer
General Counsel
Rui L. Avelar
Chief Medical Officer, Head of Research & Development
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 3.55 |
Price To Book (MRQ) | 5.61 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 378.85 |
LT Debt To Equity (MRQ) | 378.85 |
Return on Investment (TTM) | -37.15 |
Return on Equity (TTM) | -33.54 |
* EVOLUS STRENGTHENS BALANCE SHEET; SECURES $40 MILLION INVESTMENT
* EVOLUS PROVIDES UPDATE ON UNITED STATES INTERNATIONAL TRADE COMMISSION (USITC) CASE
* EVOLUS - ON JUNE 1, ADMINISTRATE LAW JUDGE ASSIGNED TO ITC ACTION ISSUED DECISION EXTENDING TARGET DATE FOR INITIAL DETERMINATION BY JUDGE TO JULY 6
* EVOLUS REPORTS FIRST QUARTER 2020 RESULTS AND PROVIDES BUSINESS UPDATE
* EVOLUS INC - REDUCTION IN COMPANY'S HEADCOUNT BY OVER 100 EMPLOYEES, WHICH REPRESENT A REDUCTION FROM 235 EMPLOYEES AS OF DECEMBER 31, 2019
* EVOLUS INC - WE PLAN TO INTRODUCE A NEW STIMULUS PROGRAM, EXECUTED THROUGH OUR FULLY INTEGRATED DIGITAL PLATFORM
* EVOLUS PROVIDES UPDATE ON INTERNATIONAL TRADE COMMISSION (ITC) CASE
Medical aesthetics company Evolus Inc <EOLS.O> on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's <AGN.N> Botox, which has dominated the medical aesthetics market for more than a decade.
Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.
(This Feb. 1 story has been corrected to remove reference to dosage in paragraph 7)
* EVOLUS, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF COMMON STOCK
* EVOLUS INC SEES IPO OF 5 MILLION SHARES PRICED TO BE BETWEEN $12 AND $14 PER SHARE – SEC FILING
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.